ERICH F. SCHINAGL, M.D.; RIDA ALI, PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: We believe that the review article on dextran 40 by Data and Nies (Ann Intern Med 81:500-504, 1974) deserves comments on the "paradoxes" reported by the authors from their selective review of the dextran 40 literature.
Dextran 40 is neither an anticoagulant nor an antiplatelet agent. Because increased platelet aggregation, blood viscosity, and elevated plasma fibrinogen concentration may lead to disseminated intravascular coagulation or shock lung, or both, in severely traumatized patients (1), many clinicians would regard decreased concentration of factors V, VIII, and IX (due largely to hemodilution) and decreased platelet adhesiveness (but not count) after
SCHINAGL EF, ALI R. Dextran 40. Ann Intern Med. ;82:722–723. doi: 10.7326/0003-4819-82-5-722_2
Download citation file:
Published: Ann Intern Med. 1975;82(5):722-723.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use